Other News To Note

• AtheroNova Inc., of Irvine, Calif., initiated the first shipment of AHRO-001 active pharmaceutical ingredient to R&D partner CardioNova Ltd., a Russian subsidiary of Maxwell Biotech Group, for Phase I and II studies in AHRO-001's initial application in the treatment and prevention of atherosclerosis. AHRO-001 uses natural compounds to reduce atherosclerotic plaque deposits through delipidization, which dissolves plaques in artery walls and enables them to be removed by natural body processes.